Plans for Analysis of USG Emergency Plan Multi-Country ART Program John Aberle-Grasse CDC, Global AIDS Program U.S. Department of Health and Human Services.

Slides:

Advertisements

Similar presentations

Overview/Importance of HMIS

Advertisements

A Guide to Monitoring and Evaluating HIV/AIDS Care and Support.

Nigeria Case Study HIVAIDS Specific Slides. ANALYZING AND INTERPRETING DATA.

REASONS FOR LONG-TERM LOSS TO FOLLOW UP OF ADULT ART PATIENTS IN SOUTH AFRICA: A PROSPECTIVE, QUALITATIVE STUDY METHODS RESULTS POLICY RECOMMENDATIONS.

Clinical Alliances and Partnerships Raul A. Romaguera, DMD, MPH Division of HIV/AIDS Prevention Centers for Disease Control and Prevention March 11, 2004.

CDC Mozambique Transition Monitoring Approach 8 th Annual Track 1 meeting, August 12, 2010 Charity Alfredo CDC-Mozambique.

Absorption, Retention and Empowerment

Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.

Guidance for Year 06 Track 1.0 ART Program Continuation Applications Tedd Ellerbrock, MD Team Leader, HIV Care and Treatment, GAP, CDC Barbara Aranda-Naranjo,

Update: National AIDS Programmes FHI, Horizons, HHS-CDC & HRSA, Macro, Measure, Synergy, USAID, WHO,UNAIDS Katherine Marconi, Ph.D., MS Presenter A Guide.

Workshop on ART in Pregnancy, Breastfeeding, and Beyond Adult Treatment and PMTCT/Pediatric Technical Workgroups US Office of the Global AIDS Coordinator.

John Aberle-Grasse CDC GAP Strategies for Building National-Scale Longitudinal Patient Monitoring Systems for HIV Treatment and Care Lusaka, October 2-5,

Integrating Evidence-Based Practice Into QI to Improve Patient Outcomes in HIV: Viral Load Suppression Victoria Lieb, ACRN, MPH; Carla Rossi, MD; Jaime.

Cross-cutting Capacity Building Needs of Proposed Local Partners Philippe Chiliade, MD,MHA HHS / HRSA Maputo, Mozambique August 12, 2010.

Stable Outcomes and Costs in South African Patients’ Second Year on Antiretroviral Treatment Lawrence Long, Health Economics Research Office, Wits Health.

The Implementation of the WHO Asia Pacific Treatment Metrics Dr. YU, Dongbao WHO Regional Office for the Western Pacific 20 July, 2014 Antiretroviral Treatment.

Evaluating Cost Gavin Steel, Jude Nwokike, Mohan P. Joshi & Mupela Ntengu Development and Implementation of a Multi-Method Medication Adherence Assessment.

Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.

Assessment of Program Evaluation Activities in Tuberculosis Control Programs — United States, 2009–2010 Silvia M. Trigoso, MPH Fellow, Public Health Prevention.

Presentation Title Presenter(s) Centers for Disease Control and Prevention AIDS Turning the Tide Together.

Meredith Carr, JD J. Stan Lehman, MPH David W. Purcell, JD, PhD Division of HIV/AIDS Prevention Centers for Disease Control and Prevention July 25, 2012.

International Network for the Rational Use of Drugs Initiative on Adherence to Antiretrovirals (INRUD-IAA) Measuring Adherence Using Paper-Based Facility.

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Effects of Patient Tracking Systems and Providers Incentives on Patient Appointment Keeping Rwanda Pilot Study Report Nyamusore Jose 1 *, Hinda Ruton 1,

10 Recommendations to Help Strengthen and Expand HIV Care and Treatment Services during the Next 12 Months Adult Treatment Technical Workgroup US Office.

Attrition in HIV Care Attrition in HIV Care: Key Operational Challenge in implementing HIV Care and Treatment in Tanzania G R Somi _________ Ministry of.

Results of the Track 1.0 Antiretroviral Therapy Program February June 2007 Barbara Aranda-Naranjo, PhD, Director HIV/AIDS Bureau, Global HIV/AIDS.

Avenida Hotel Maputo, Mozambique August 10-12, 2010 The 8th Annual Track 1.0 ART Program Meeting.

ICAP Quarterly Master Slide Set April-June Site Census What: Ongoing, real-time inventory of all planned, current, and closed ICAP sites. Supported.

2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.

Progress toward COP 12 targets Mozambique-ICB October

PEPFAR Plans for Initiating ART and Providing Laboratory Services Tedd V. Ellerbrock, MD, FACOG Global AIDS Program Centers for Disease Control and Prevention.

Orientation on HIV care and ART Recording and Reporting System.

HIV Care Continuum, Georgia, United States, 2011 Presented to American Public Health Association, Annual Meeting Presented by Deepali Rane, MBBS, MPH,

INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,

Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.

Community-based Adherence Clubs improve outcomes for stable ART patients: Outcomes from Cape Town, South Africa Anna Grimsrud 1, Maia Lesosky 1,2, Cathy.

HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.

HIV Care Continuum Persons Living With HIV, Georgia, 2012.

Failure to Initiate ART, Loss to Follow-up and Mortality among HIV-infected Patients during the pre-ART period in Uganda Elvin H. Geng 1, Winnie Muyindike.

Monitoring Transition of Harvard Support to Management and Development for Health (MDH), Tanzania Mary Mwanyika-Sando, MD 8 th Annual CDC/HRSA Track 1.0.

Data dissemination meeting February 28, 2007 ICAP New York.

Philippe Chiliade, MD, MHA Technical Advisor, Clinical Care, FHI 12 August 2008 Family Health International Implementing HIV Care & Treatment Progress.

Sub module 1 Introduction to HIV care and ART recording and reporting system.

Mövenpick Royal Palm Hotel Dar es Salaam, Tanzania August 4-6, 2009 The 7th Annual Track 1.0 ART Program Meeting.

Scaling-up HIV Prevention, Care and Antiretroviral Therapy at Primary Health Centers A WHO/PEPFAR Collaboration.

HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.

Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

HIV Care Continuum New Diagnoses, 2011, Georgia. Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States Percent

Melanie McNeil, Esq. State Long-Term Care Ombudsman Office of the State Long-Term Care Ombudsman

ICAP Quarterly Master Slide Set July-September 2007.

PROYECTO VIDA BIENESTAR HUMAN SERVICES, FRANK GALVAN, PH.D.

Progress toward COP 12 targets DRC October

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

| Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official.

Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.

From Aggregate Indicators to Impacting Patients - Data Use to Inform Treatment and Improve Care Ian Wanyeki Track 1.0 Implementers Meeting Dar Es Salaam.

HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,

Continuum of Surveillance Updates from Epidemiological Services New Jersey Department of Health Division of HIV, STD and TB Services (DHSTS) Annual.

Differentiated Service Delivery: Innovating for Impact

NYSDOH AIDS Institute Quality of Care Program eHIVQUAL

HIV Care Continuum in Manhattan

Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda

Implementation of the Appointment Spacing Model of Differentiated Service Delivery in Ethiopia: Successes and Challenges Tamrat Assefa1, Zenebe Melaku1,

Tuberculosis and the President’s Emergency Plan for AIDS Relief

Retention: What It Means for You

Treatment Outcome among patients on ART in Southern Tanzania: Does Time of ART initiation Matter?

Presentation transcript:

Plans for Analysis of USG Emergency Plan Multi-Country ART Program John Aberle-Grasse CDC, Global AIDS Program U.S. Department of Health and Human Services

Analysis Proposal Analyze the “quantity” and “quality” of HIV care and treatment programs supported by the USG multi-country partners across the 15 Emergency Plan focus countries Publish “simple” description of results in a prominent medical or public health journal, submitted in approximately 9-12 months

Analysis Rationale The Emergency Plan ART program is very large and complex and should be monitored and evaluated to assess progress both in scale-up and service quality Program success (and challenges) should be published to inform the medical and scientific community and the US public that supports the program

Analysis Rationale Track 1.0 grantees (4) and the Department of Defense and Family Health International provide direct ART services across multiple countries to over 1/3 of patients in the Emergency Plan This large (relatively) standardized ART program data and reporting represents a unique and significant opportunity to describe the extent and quality of HIV care and treatment being supported by the USG

Proposed Title and Authorship Working title- Scale up of Antiretroviral therapy by Emergency Plan Multi-country partners: Authorship- Emergency Plan Multi-country ART Partner and Agency Group

Analysis Based on recommendations by the US Office of the Global AIDS Coordinator Adult Treatment Technical Workgroup for description of USG-funded HIV care and treatment programs Describe services provided between Track 1.0 program start up in 2004 through Sept 30, 2007

Quantity of Program (scale up) Calculate quarterly- FY04Q4 to FY07Q4 Patients ever enrolled in HIV care Patients currently in HIV care Patients ever started on ART Patients started on ART during quarter Patients currently on ART Facilities providing ART Analysis

Quality of Program- (cohort) Proportion alive and on ART (6, 12, 24 mos) Including transfer in, excluding transfer out Median difference in CD4 from start Proportion with undetectable viral load (<400 cells/µl) Proportion started on 2nd line ART Proportion not on ART (6, 12, 24 mos) Died Stopped Lost to follow up Of those enrolled in HIV care, proportion on care at 12 months Analysis

Administration of analysis Task Force to guide and move analysis Include participants from USG agencies and grantee partner groups Contact John Aberle-Grasse at this meeting, or phone, or The USG work group includes: CDC GAP: Tedd Ellerbrock, Laura Porter, Seymour Williams, Hong-Ha Truong, John Aberle-Grasse USAID: Robert Ferris HRSA: Jin Park DoD: To be determined

ActivityDateComments Convene Task ForceSept 26 Data request sent to partnersOct 5Quantity & Quality data Quantity data dueNov 15Partners submit (routine) Data & analysis meetingNov 16-21Data problems & analysis Report for Track 1.0 completeDec 15Routine tables, etc Quantity data analysis dueJan 12Partners review Quality data dueJan 12Partners submit Quality data analysis dueFeb 15Partners review Full paper for reviewMar 28Partners review Analysis- Proposed time table

Thoughts for Discussion Do partners support this proposal? Have quarterly data from Track 1.0 partners, is data for DoD and FHI readily available? What disaggregation? (sex, age, country, partner, facility type) How best do we “simplify” and present multi- country, multi-partner “quality” analysis? Additional analysis of more detailed issues and data subsets Other thoughts?

For more information contact: John Aberle-Grasse CDC GAP 1600 Clifton Rd, MSE 30 Atlanta, GA

Analysis Specific program attributes proposed to be measured include Program scale up Facilities providing ART Patients ever started on ART Patients started on ART each quarter Patients currently on ART Patients on HV care Program quality Of persons who enrolled in ART, what proportions are alive and on ART at 6, 12, 24, and 36 months of therapy? Of those who enrolled in ART but are not currently on ART, what proportions (a) died, (b) stopped therapy, (c) transferred, or (d) were lost to follow up at 6, 12, 24, and 36 months? Of persons on ART, what is the median differential between the CD4+ cell count at baseline and the CD4+ count at 6, 12, 24, and 36 months? Of those who are on ART, what proportion have undetectable viral load (<400 cells/µL) at 6, 12, 24, and 36 months? Of persons enrolled in care (i.e., both those receiving and not receiving ART), what proportion is in care and/or on ART at 12 months?